HEALTH
Biotech Firms Reach Settlement: Xoma Corp. and Centocor Inc. have agreed to settle all outstanding litigation and disputes surrounding their competing sepsis drugs, ending more than two years of wrangling. The biotechnology rivals also agreed to forgo future claims regarding each other’s patents and patent applications for anti-endotoxin monoclonal antibodies, which treat life-threatening blood infections contracted in hospitals. Centocor agreed to pay Xoma unspecified royalties for U.S. sales of its HA-1A sepsis drug, which is sold as Centoxin overseas.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
